Pharmscope News (API). 09/22/2011. For immediate release:
Adventrx Pharmaceuticals,(ticker:ANX), has just announced formulation of its newest drug candidate, Rejuvinol-80.
Dr. Payne N. Zuffring MD, of Liechtenstein, has announced a break-through medication for the treatment of Prolonged FDA Waiting Syndrome (PFWS).
Dr. Zuffering states, "Our initial test trials of Rejuvinol-80 have clearly shown positive reverse intolerance behaviors improvement statistics in 1 out of the 2 test cases we have sampled. We feel strongly that this indicates a need to move forward with further testing in our Botswana-based research center."
In an initial limited study, Rejuvinol-80 has been shown to counteract the disheartened and impatient mood disorder (PFWS) arising within persons who own Adventrx stock and have to watch its value disintegrate as they await positive news releases which may/may not positively effect the PPS.
Rejuvinol-80, formulated from a mixture of Lemon-Grass and Lorazepam, seems to initiate a state of serenity, patience and acceptance in those shareholders who experience frequent despair.
Dr. Zuffering reports, "...that of the two test cases in the initial study, we found that one Botswanian experienced a calming effect after he ingested the Rejuvinol-80 and then read the weekly share price statements for ANX. The other test-subject went to sleep."
Dr. Zuffering feels that the scientifically blended combination of Lemon-Grass and Lorazepam will herald a new treatment bonanza for those who suffer from PFWS. Initial projections are 2 billion dollars in US sales and 15 Billion dollars worldwide.
Sentiment: Strong Sell